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Abstract 
Papillomaviruses induce a wide range of clinical conditions in humans and animals, 
ranging from asymptomatic infection, benign warts, pigmented plaques to in situ 
carcinoma and invasive squamous cell carcinomas. In dogs, entire genomic 
sequences of thirteen different papillomaviruses are described so far and that appear 
to be associated with different clinical presentations. However, neither the 
phylogenetic classification of a canine papillomavirus (CPV) nor the presence of 
distinct motifs on the genome can unanimously predict the fate of an infection on the 
individual level.  
In the present study we performed a microarray analysis of CPV associated lesions 
(CPV1, CPV3, CPV5). Ninety-six genes were at least 4 fold up or down-regulated on 
a significant level. We further investigated in CPV lesions, the RNA levels of KLK8, 
MCM5, ORC1, and PAX6, which are discussed as biomarkers in the human 
medicine. We could confirm the up regulation of these genes by qRT PCR.  
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Zusammenfassung 
Papillomaviren verursachen eine breite Palette von Krankheitsbildern bei Mensch 
und Tier, welche  von asymptomatischen Infektionen, gutartigen Warzen, 
pigmentierten Plaques, in situ Karzinomen bis zu invasiven Plattenepithelkarzinomen 
reichen. Bei Hunden sind die gesamten genomischen Sequenzen von dreizehn 
verschiedenen Papillomaviren beschrieben, die mit unterschiedlichen klinischen 
Erscheinungsbildern verbunden sind. Allerdings können weder die phylogenetische 
Klassifizierung eines Hundepapillomavirus (CPV) noch das Vorhandensein von 
unterschiedlichen Genregionen genau den Verlauf einer Infektion auf individueller 
Ebene vorhersagen. In der vorliegenden Studie führten wir eine Microarray-Analyse 
von CPV assoziierten Läsionen (CPV1, CPV3, CPV5) durch. Die Expression von 
sechsundneunzig Genen war signifikant mindestens 4-fach rauf oder runter reguliert. 
Weiter haben wir die RNA Levels von KLK8, MCM5, ORC1 und PAX6, die als 
Biomarker in der Humanmedizin diskutiert werden in Papillomavirus Läsionen 
untersucht. Wir konnten durch qRT-PCR die erhöhte Expression dieser Gene 
bestätigen.  
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Abbreviations:  
bp   Base pair 
cDNA  Complementary deoxyribonucleic acid 
CPV  Canine papillomavirus 
cRNA  Complementary ribonucleic acid 
DNA  Deoxyribonucleic acid 
FGCZ  Functional Genomic Center Zurich 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
KLK8  Kallikrein related peptidase 8 
MCM5 Minichromosome maintenance protein 5 
mRNA Messenger ribonucleic acid 
MUSTN1 Musculoskeletal, embryonic nuclear protein 1 
ORC1  Origin of recognition complex 1 
PAX6  Paired box gene 6 
PVs  Papillomaviruses 
qRT PCR Quantitative real time polymerase chain reaction 
RNA  Ribonucleic acid 
RT  Reverse transcription 
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Abstract 
Objective – To detect genetic biomarkers for outcome of papillomavirus infections of 
dogs.  
Animals – 3 healthy adult dogs, 5 CPV affected dogs. 
Procedures - In the present study we performed a microarray analysis of CPV 
associated lesions (CPV1, CPV3, CPV5). 
Results - Ninety-six genes were at least 4 fold up or down-regulated on a significant 
level. We further investigated the RNA levels of KLK8, MCM5, ORC1, and PAX6, 
which are discussed as biomarkers in the human medicine. We could confirm the up 
regulation of these genes by qRT PCR. 
Conclusions and Clinical Relevance - Furthermore, enrichment analysis were 
performed and revealed pronounced dysregulation of genes whose products being 
part of the cell cycle regulation.  
 
Introduction 
Papillomaviruses (PVs) are associated with a wide range of clinical conditions, 
varying from mild benign symptoms to cancer, but also with asymptomatic 
infections.1 To date, the genomic sequences of more than a dozen different canine 
PVs (CPVs) have been uncovered and partially characterized.2–16 Their 
phylogenetical classification correlates at least partially with the observed clinical 
conditions. For example, it appears that the classical benign oral papillomatosis is 
induced almost exclusively by a PV belonging to the Lambda Genus (CPV1) while 
pigmented plaques have thus far only been found associated with PVs of the Chi-
Genus (CPVs 3,4,5,8,9,10,11,12,14). However, the infected host is likely to 
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contribute as much as the virus itself to a potentially malignant outcome of these 
infections. Yet, host responses towards the various CPVs have not yet been studied 
to great detail. Since PVs generally do not replicate in cell cultures, it is difficult to 
study the details of these infections in the context of experimental inoculations. 
Therefore, we set out to carry out such studies by making use of material obtained 
from rare clinical cases, which could be traced back to one of those viruses. 
Specifically, we analysed by microarray CPV1-, CPV3-, and CPV5-associated 
lesions as well as normal skin from clinically healthy dogs. First, viral mRNA 
expression and second, the patterns of cellular mRNA expression patterns were 
addressed. As a result, we were able to describe for the first time individual cases of 
the host response in lesions associated to these three CPVs. By comparing the 
various patterns, we detected sets of genes that may be suitable to distinguish the 
three viruses as well as patterns that are common to either pairs of the viruses or 
even to all three types of CPVs. Accordingly, we came up with a set of three genes, 
whose expression levels may be able to provide clinical markers for malignancy.  
 
Material and Methods 
Cases 
Biopsy samples were collected from dogs infected by CPV1, CPV3 or-, CPV5 as well 
as from healthy dogs. Healthy dogs were defined as clinically free of any skin lesions 
and negative in PV-PCR (see below). Samples infected by CPV1 derived from 
mucous membrane and skin warts collected in three dogs. CPV3 samples were 
taken from one dog with viral plaques and virus-harbouring squamous cell 
carcinomas. CPV5 samples were taken from one dog with viral plaques and virus-
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harbouring squamous cell carcinoma in situ. More details about these clinical cases 
have been provided elsewhere.5, 8  
Sampling 
Biopsy samples (0.5g – 2g) of lesional or clinically healthy tissue were collected and 
were immediately stored at -80°C until further processing. Three control samples 
were taken from freshly euthanized dogs with macroscopic healthy skin and were 
stored in an RNA storage buffer a according to the manufacturer’s protocol. The 
absence of CPV DNA was confirmed by PCR using primer combinations 
FAP59/FAP64, CP4/CP5 and canPV/FAP64 (Table 1).11,17,18 
RNA and DNA Extractions 
A half pinhead sized piece of tissue was homogenized in liquid nitrogen using mortar 
and pestle. Total RNA was then extracted from the homogenate with a commercial 
RNA extraction kit b according to the manufacturer`s instructions. Extracted RNA was 
eluted in 50 µl RNase free water and to get rid of putative remnant DNA additionally 
digested using 1µl recombinant, RNase-free DNase I c. After incubation for 15 
minutes at 37° C the DNase was heat-inactivated at 75° C for 10 minutes. The RNA 
was stored at -80° C after the concentration was measured d. DNA was extracted 
from a half pinhead sized piece of healthy skin using a commercial extraction kit e 
according the manufacturer`s instructions. The DNA was eluted in 200 µl and the 
concentration was measured.  
RNA and DNA amplification 
Reverse transcription. The RNA was converted to cDNA with reverse transcriptase f 
using random primers according to the manufacturers instructions. 
PCR: PCR was performed with a ready PCR mix g. Primers are shown in Table 1. 
PCR was implemented in a total volume of 25 µl, containing 12µl from the PCR mix, 8 
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µl water, 2 µl of each forward and reverse primer (10µM each), with 1µl extracted 
DNA or cDNA as template. In case of all PV-type-specific primer pairs, the PCR 
program started with a denaturation for 3 min at 94°C, followed by 40 cycles of 30 s 
at 94°C, 30 s at 50°C and 30 s at 72°C. The PCR program for canPVf/FAP64 primers 
started with a denaturation step for 5 min at 94°C, followed by 45 cycles of 60 s at 
94°C, 60 s at 50°C, 60 s at 72°C and a final elongation for 5 min at 72°C. The PCR 
program for CP4/CP5 and FAP59/FAP64 primers started with a denaturation step for 
3 min at 94°C, followed by 40 cycles of 30 s at 94°C, 30 s at 42°C and 30 s at 72°C. 
PCR products were loaded onto 1% agarose gels containing ethidiumbromid and 
analyzed after 45 minutes in an electric field of 5 V cm-1 in TAE buffer. 
Agilent GE Microarray Experiment Description 
The custom arrays were designed h based upon 42034 probe sets of Canis lupus 
familiaris Agilent standard array (44k x 4 chip format). Additional groups of probesets 
were created by tiling the sequences of CPV1, CPV3, CPV5 and GFP every 30bp, 
what in the case of Agilent 60bp probe results in double coverage of every fragment 
of the viral genome. Consequently all changes in expression may be traced with the 
precision down to 30bp (Agilent custom design ID:028307).  
The quality of the isolated RNA was determined i. Only samples with a 260 nm/280 
nm ratio between 1.8–2.1 and a 28S/18S ratio within 1.5–2 were further processed. 
Total RNA samples (100ng) were reverse-transcribed into double-stranded cDNA in 
presence of RNA poly-A controls j. The double-stranded cDNAs were in vitro 
transcribed in presence of Cy3-labelled nucleotides using a commercial kit k. The 
Cy3- cRNA was purified using a commercial kit l and its quality and quantity was 
determined. Only cRNA samples with a total cRNA yield higher than 2 μg and a dye 
incorporation rate between 8 pmol/ μg and 20 pmol/ μg were considered for 
hybridization. 
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Cy3-labeled cRNA samples (1.65 μg) were mixed with a Agilent Blocking Solution, 
subsequently randomly fragmented to 100-200 bps at 65°C with Fragmentation 
Buffer, and resuspended in Hybridization Buffer using a commercial kit m. 
Target cRNA Samples (100μl) were hybridized to the Canis familiaris Agilent 
standard array for 17h at 65°C. Arrays were then washed using Agilent GE Wash 
Buffers 1 and 2 according to the manufacturer instructions n. Fluorescent intensity 
emitted by the labeled target was measured o and raw data processing was 
performed p. Quality control measures were considered before performing the 
statistical analysis. These included, inspection of the array hybridization pattern 
(absence of scratches, bubbles, areas of non-hybridization), proper grid alignment, 
performance of the spike-in controls (linear dynamic range between 5 orders of 
magnitude) and number of green feature non uniformity outliers (below 100 for all 
samples) 
Initial experimental design included three replicates of CPV1, CPV3, CPV5 and 
control samples, allowing the margin of safety for the statistical power of the 
analyses. Thus 3 chips in the 44k x4 format were needed. After scanning, the quality 
control was performed, including scatterplots of all the arrays against the mean of 
their treatment groups, expression value histograms for arrays, correlation plots of 
samples, hierarchical clustering of samples (Pearson correlation as the similarity 
measure, Ward distance to cluster) and heatmaps of top probes. A pairwise 
comparison from CPV1, CPV3 and CPV5 versus control was done by t-test and fold 
change. Afterwards a one-way ANOVA with F-test was applied. All the quality 
controls described above and initial analyses have been performed using lab 
management system of the FGCZ q. Further analyses of the viral genome expression 
has been performed by creating separate datasets for the custom probes, setting 
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them in order as in the original genome and checking the differences between 
treatments and plotting them according to the viral genome coordinates. 
Affected pathways 
Genes that were identified to be up- or down-regulated by the microarray 
experiments were subsequently screened. Basically, all genes with at least a four-
fold up- or down-regulation in expression compared to the controls were checked to 
determine if they might be relevant during CPV infections. Furthermore, it was 
evaluated whether these genes belong to known cellular pathway maps, process 
networks, and GO processes. For this purpose, the canine annotation was 
transformed into the human annotation. The 13489 transformed annotated genes 
were filtered by 1.74 (20.8)-fold up- or down-regulation and P-Values of 0.1 and then 
used r to identify enriched pattern in the data sets.  
Quantitative RT-PCR 
Genes that were identified to be up- or down-regulated by the microarray 
experiments were subsequently screened s for their relevance in causing cancer. All 
genes with at least a four-fold up- or down-regulation in expression compared to the 
controls were checked. Some potential tumor markers were identified. Consequently 
a quantitative RT-PCR (qRT-PCR) was applied to estimate the expression level of 
the cellular transcripts of MCM5, ORCI, PAX6, KLK8 and GAPDH. The primers 
(Table 1) were designed t. The amplimers of RT-PCR using the newly designed 
primers were cloned into a plasmid u according to the manufacturers instructions. 
Sensitivity and specificity of the primers were evaluated by standard curves on serial 
dilutions of the cloned templates. (Figure 1) The quantitative PCR was performed 
using a real time PCR detection system v according to the manufacturers 
instructions. In brief, qRT PCR was implemented as duplicates in a total volume of 20 
µl, containing 10 µl detection mix w, 0.6 µl Primer forward, 0.6 µl Primer reverse, 3.8 
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µl sterile water and 5 µl template. A two step protocol was applied. The following 
cycles were run:(i) 7 min at 95°C, (ii) 41 cycles of 10s at 95°C and 30s at 60°C, (iii) 
95°C for 1 min and (iv) 55°C for 1 min. Increase setpoint temperature after cycle 2 by 
0.5°C. A relative quantification was performed with the host gene GAPDH compared 
to healthy skin with the following formula: ΔΔCt = (Ctsample - CtGAPDH_sample ) – (Ctmock - 
CtGAPDH_mock ) Calculations of statistic significance between the gene expression of 
particular samples were performed x using t-test.  
 
Results 
Microarray analysis  
Biopsy samples from CPV-positive and CPV-negative tissues (see cases in M+M) 
were used to evaluate by Microarray analysis (1) the relative RNA expression of 
CPV1, CPV3, and CPV5 as well as (2) the corresponding status of host gene 
expression. To estimate the viral RNA transcription, tiling probes representing in an 
overlapping manner the entire genomes of CPV1, CPV3, and CPV5 were included in 
the arrays as custom probes. The expression profiles along the viral genomes are 
shown in Figure 2. Indeed, signals corresponding to these probes, were elevated in 
virus infected tissue samples, whereas the signals of the healthy skin samples 
remained on background levels. Interestingly, the signal levels peaked in the 
proximity of the predicted polyadenylation signals on the viral genomes, suggesting 
that both early and late viral gene expression took place in the infected tissue 
samples. Based on these results, we conclude that the viruses were active in the 
affected tissues and not merely present.  
The expression of the host genes was not measured along the entire RNA molecules 
but on the basis of a few representative sequences that had been previously 
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optimized for that purpose. Of note, the expression levels of several cellular 
transcripts were altered in virus-infected tissue compared to healthy skin. 
Furthermore, differences were detected between the different virus infected samples. 
In CPV1 infected samples 21 genes were at least four fold up- and 15 genes down-
regulated compared to control samples. Of these genes, 18 were only up- regulated 
in CPV1 infected samples (Table 2; Figure 3a). Samples of the CPV3 infected dog 
showed an at least four fold higher expression of 13 genes and a lower expression of 
17 genes compared to the control samples whereby 10 genes were up-regulated and 
9 down-regulated only in CPV3 samples (Table 3; Figure 3a). Samples of the CPV5 
infected dog showed the highest number of at least four fold up- or down-regulated 
genes. Thirty-one genes were up and 16 genes down-regulated with 28 of these 
genes beeing up- and 12 genes down-regulated only in CPV5 samples (Table 4; 
Figure 3a). Carbonic anhydrase II was up-regulated in both, CPV1 and CPV5 and 
diacylglycerol lipase beta in both, CPV3 and CPV5 (Table 5; Figure 3a). In case of 
CPV1 and CPV3 samples, 4 identical genes were down and one was up regulated 
(Table 5a). Only one gene (KLK8) was up- and 4 genes (MUSTN1, CCRL1, VIT, 
MT3) down-regulated in all samples infected with one of the three examined viruses 
(Table 5d; Figure 3a).  
Enrichment analysis of the genes was conducted in order to identify pathway maps, 
process networks, and GO processes affected by viral infections (Table 6). Genes 
relevant in cell cycle regulation, DNA repair, and proteolysis were enriched in the 
individual data sets. Interestingly, the enrichment was more pronounced in samples 
from CPV5 than from CPV3 and only marginally from CPV1. Between 40% and more 
than 60% of genes assigned to the most enriched pathway maps, especially those 
associated with cell cycle regulation and DNA repair were differently expressed by 
CPV5 infection, but only 10% to 45% by CPV3 and 5% to 15% by CPV1 infection. 
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The genes assigned to different process networks were 30% to 50% differently 
expressed in CPV5 infected tissue but only 5% to 20% in CPV3 and around 5% in 
CPV1 infected tissue. A similar percentage of genes assigned to GO processes were 
enriched for the virus-infected tissue. Of note, the p-values for the CPV5 sample 
enriched genes were highly significant (10E-6 to 10E-44) and most significant (10E-1 
to 10E-30) for CPV3 sample enriched genes. These results suggest that cell cycle 
regulation and DNA repair are deeply affected by CPV5 infection and markedly 
affected by CPV3 infection: On the contrary, CPV1 infection does not seem to 
markedly affect these pathways. 
qRT PCR for potential diagnostic markers  
Among the up-regulated genes in the samples were KLK8, MCM5, ORC1, and 
PAX6. These might serve as potential biomarker in dogs like, according to the 
literature, in humans. The kallikrein related peptidase 8 (KLK8) is a serine protease 
and is expressed in the extracellular matrix. The minichromosome maintenance 
protein 5 (MCM5) and the origin of recognition complex 1 protein (ORC1) play a role 
in the cell cycle. The paired box gene 6 (PAX6) product is a transcription factor in 
embryogenesis. 
In order to confirm these up-regulations real time quantitative RT-PCR assay (qRT-
PCR) was developed. The similar slopes (Figure 1) indicate similar efficiencies of the 
qPCR, which allows the use of the ∆∆Ct method calculation of relative expression to 
GAPDH as internal control. The newly developed qRT-PCR was used for evaluation 
of the expression levels of the marker genes. KLK8 was up - regulated (between 23 
and 26 times) in all virus infected samples to a significant level compared to the 
control samples (Table 7). MCM5 was only significantly up-regulated in CPV3 
infected samples (7 times). In CPV5 infected samples MCM5 was up-regulated too 
(2.9 times), but not to a significant level (Table 7). The ORC1 gene expression was 
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highly significant up-regulated in CPV3 (6.8 times) and CPV5 (3.2 times) infected 
samples, while there was no difference between CPV1 and control samples. The 
expression of the PAX gene was also highly increased in CPV3 samples (34.4) and 
somewhat higher in CPV5 samples (3.4) compared to control samples. In contrast 
the PAX6 gene did not differ from the controls in samples from CPV1 infected dogs. 
(Table 7). In conclusion, the qRT-PCRs confirmed the micro array results.  
 
Discussion 
In this study, we have evaluated in a comparative manner the relative transcription 
levels of three CPVs in infected tissues obtained from natural infections in patients 
and analyzed the corresponding host gene expression patterns. Due to the scarcity 
of cases and corresponding rarity of fresh material, we can only describe the data 
found in a few individual cases. However, in the absence of viruses that can be 
grown in cell culture, this still may provide a set of reference data, which certainly 
should be challenged once experimental models become available. Several genes 
were found to be up- or down-regulated in canine skin affected by CPV1, CPV3 or 
CPV5 infection (Tables 2 to 5, 7). According the microarray results three genes, 
which were only up- regulated in CPV3 samples (MCM5, ORC1L, PAX6) were 
identified (Figure 2). MCM5 plays an essential role in the cell cycle, as it is 
responsible for the generation of a prereplicative complex during G1 phase. MCM5 
protein was previously identified as a potential biomarker for prostate cancer and 
genito-urinary tract cancer, that can be detected in the urine.19,20 Furthermore, it has 
been discussed21, as a marker for the diagnosis of cervical dysplasia, as it increases 
proportionally with the severity of the lesions. MCM5 is indirectly up-regulated by the 
human PV (HPV) E7 Protein. The (HPV) E7 protein binds the retinoblastoma protein 
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(pRb), it leads to a releasing of inhibition of E2F and this leads to an up-regulation of 
MCM5.21 CPV2 E7 is required for degradation of pRb.22 In other studies, the MCM5 
has been described as a diagnostic marker for malignancy in pancreaticobiliary 
disease and oesophageal cancer by detection in bile or gastric aspirates.23,24 The 
ORC1 is involved in the initiation of DNA replication. In a gene expression study of 
HPV 16 E6 transgenic mice, the ORC1 transcription was up-regulated.25 It was also 
shown that in HPV positive head and neck cancers the ORC1 was highly up-
regulated compared to HPV negative ones.26 It might be, that the CPV3 and CPV5 
are also responsible for the up-regulation of ORC1 in the dog samples included here. 
Maybe the ORC1 could be used as a malignancy marker in CPV affected dogs. 
The PAX6 is a member of the PAX gene family which encode a set of transcription 
factors in embryogenesis.27 Transgenic mice expressing PAX6, cystic adenoma of 
the pancreas was induced.28 Enhanced PAX6 expression is associated with 
carcinomas in the breast and pancreas.28,29 Interestingly in contrast, PAX6 is also 
discussed as a marker for a favorable outcome in gliomas and that PAX 6 may have 
a tumor suppression function in gliomas.30,31 In our cases the PAX6 gene is up-
regulated in CPV3 and CPV5 samples which are rather associated with malignant 
tumors. 
In the samples analyzed here one gene was found to be up-regulated in CPV1, as 
well as CPV3 and CPV5 infected skin (Table 5d; Figure 3a) This gene, encoding for 
the Kallikrein related peptidase 8 (KLK8) a serine protease which is responsible for 
the degradation of fibronectin in the extracellular matrix. It is down-regulated in breast 
cancer but up-regulated in cervical, colon and ovarian cancer. Therefore, KLK8 and 
other KLK are discussed as a biomarker for the outcome and detection of various 
tumors in human medicine.32–35 KLK8 is also discussed as an early biomarker for the 
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detection of endometrial carcinomas, as low grade endometrial tumors are 
associated with a higher expression of KLK8 than high grade ones and normal 
tissue.33 KLK8 was found to be down-regulated in HPV positive head and neck 
cancers compared to HPV negative ones and normal tissue.36 It might be that the 
KLK8 is influenced by PV infection. As KLK8 was up-regulated in all our CPV 
infected samples, we suggest that it might serve as a potential marker for CPV 
infection in an already existing skin tumor. 
In order to reveal which groups of genes were affected by CPV infections, gene 
enrichment analysis was conducted. These analyses clearly demonstrate that a set 
of genes, which is involved in the cell cycle regulation, is significant differently 
expressed in CPV5 infected tissue, less significant in CPV3 and only marginally 
significant in CPV1 infected tissue compared to control tissue. However, due to the 
low number of samples covered in this study, a sound biological conclusion could not 
be drawn. It may be worthwhile to test the potential usefulness of these markers in 
future clinical studies.  
In summary, we have identified three potential markers, KLK8, MCM5 and ORC1 of 
cancer transformation in CPV infected tissues. Further studies are warranted to 
analyze more samples and to check whether the expression of the same or similar 
genes is also modified in further affected dogs.  
 
Footnotes 
a. RNAlater, Roche, Rotkreuz, Switzerland. 
b. NucleoSpin® Total RNA Isolation kit, MACHERY-NAGEL, Düren, Germany. 
c. RNase free DNase, Roche, Rotkreuz, Switzerland. 
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d. Nanodrop 1000 Photospectrometer, NanoDrop Technologies, Wilmington, DE. 
e. QIAamp® DNA Mini Kit, QIAGEN, Germantown, MD. 
f. Reverse Transcription (RT) System, Promega, Madison, WI. 
g. REDTaq® ReadyMix™ PCR Reaction Mix with MgCl2, SIGMA-ALDRICH, Buchs, 
Switzerland. 
h. Agilent eArray software (https://earray.chem.agilent.com/earray/) 
i. Bioanalyzer 2100, Agilent, Basel, Switzerland. 
j. RNA Spike-In Kit, One-Color, Agilent, Basel, Switzerland. 
k. Low Input Quick Amp Labeling Kit, one-color, Agilent, Basel, Switzerland. 
l. RNeasy mini kit, QIAGEN, Germantown, MD. 
m. Gene Expression Hybridization Kit, Agilent, Basel, Switzerland. 
n. One-Color Microarray-Based Gene Expression Analysis Manual. 
o. Agilent Microarray Scanner, Agilent, Basel, Switzerland. 
p. Agilent Scan Control and the Agilent Feature Extraction Software Version 10 
q. based on R/BioConductor scripts included in the bFabric of FGCZ 
r. GeneGO (http://www.genego.com) 
s. Wikigenes (http://www.wikigenes.org/) 
t. NCBI Primer blast software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
u. pCR 2.1-TOPO plasmid, Life Technologies, Zug, Switzerland. 
v. iCycler, BIO RAD, Cressier, Switzerland. 
w. IQTM SYBR Green Supermix, BIO RAD, Cressier, Switzerland. 
x. STATISTICA, StatSoft, Tulsa, OK. 
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Figure legends 
Figure 1: Standard curves of qPCR Serial dilutions of cloned cDNA were used in 
qPCR assay. Equation and R2 values from linear regression analyses are shown.  
Figure 2: Viral gene expression in tissue samples. Signal levels of CPV tilling 
probes representing CPV1 (a), CPV3 (b), and CPV5 (c) in infected tissue samples 
and control samples are shown with red lines and black lines, respectively. 
Polyadenylation signals and early and late gene regions are indicated.  
Figure 3: Highly significant at least four fold up and down-regulated genes in 
samples infected with CPV1, CPV3 and CPV5. (a) total amount of up and down-
regulated genes in one, two or all three virus affected samples; (b) three possible 
indicator genes for CPV3 diagnostics (MCM5, ORC1L, PAX6) and one possible 
indicator gene for CPV infections in general (KLK8). 
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Tables 
Table 1: Primerlist 
Primer name Primer forward  5'-3' Primer reverse 5´-3 
Used for conventional PCR   
CPV1 E1 aga ctg agg atg gtg gtt gg ggc gtt aag cta atg ctt gc 
CPV1 E2 gca ctg gtc att gct cag aa ccc agg tgt caa act cat cc 
CPV1 E6 ttt gct tga tct gtc gct tg gtt ctt tgt ccg cct cac tc 
CPV1 E7 cgc aac cct ttt gga tat tg cta gcc gcc atg gtc aag 
CPV3 E1 agg gag gac aat agg cag gt ggt tag acg ctc gca tta gc 
CPV3 E2 tgc agg aca cca gct atg ag tgt ggt gct ggt gac aga tt 
CPV3 E6 gag tgt ctc tgt gcg cga ta cac cgc cct ctc act ttt t 
CPV3 E7 ttg gga aag acg cta ctt tga ctc cat ggt caa agc ggt ag 
CPV5 E1 agg gag gac aat agg cag gt taa atg gcc tgg tca act cc 
CPV5 E2 ctg tca gat cag gtc cag ca tcc gtg aaa tac acg tgg tg 
CPV5 E6 atg gag cct tgc agg tct ta gcc ctc tga cct ttt tga at 
CPV5 E7 ttg gga aag acg cta ctt tga aga ccg gac agc aga atg at 
canPVf / FAP64 CPV L1
6
 ctt cct gaw cct aay mak ttt gc ccw ata tcw vhc atn tcn cca tc 
FAP59/64 HPV L1
17
 taa cwg tig gic ayc cwt att ccw ata tcw vhc atn tcn cca tc 
CP4 / CP5 HPV E1 atg gta car tgg gca twt ga gag gyt gca acc aaa amt grc t 
Used for quantitative PCR 
ORC1L aac ggc att tgc tgg gac gga gcc caa agc tac tac ctg cac c 
PAX6 gac aga cac agc cct cac aa tgc agg agt acg agg agg tc 
Dog GAPDH tct ggc aaa gtg gat att gtc gcc ct cag cct tga ctg tgc cgt g 
MCM5 gct gtc gca aca cgc tta gt cca cac act tgc act tgt ca 
KLK8 
gga agc ctg ggc agg aca ct g agc cgg acg ccc tgg aac aaa g 
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Table 2: High significant (p<0.01) at least four fold up or down regulated gene 
expression in only CPV1 affected tissue samples compared to the control. 
Identifier log2 
Ratio_CPV1 
(fdr_CPV1) 
PrimaryAccession GeneSymbol GeneName Description 
Up regulated genes 
A_11_P106901 3,434 (0,5339) ENSCAFT00000036982       
A_11_P058156 3,281 (0,5339) ENSCAFT00000025757 SERPINE2 serpin peptidase inhibitor clade E  cell adhesion 
A_11_P084851 2,983 (0,5339) ENSCAFT00000004629 AMTN amelotin Ameloblast-specific Protein 
A_11_P159703 2,605 (0,5339) TC53629     TTLL9 protein partial (29%)  
A_11_P0000018450 2,394 (0,5733) DN874207     Dog eye cornea 
A_11_P0000021406 2,354 (0,5369) ENSCAFT00000013192 HK2 hexokinase 2 Glycogen synthesis 
A_11_P0000033381 2,353 (0,5339) ENSCAFT00000020046 KCNK2 potassium channel subfamily K 
member 2 
ionic channel 
A_11_P0000022037 2,331 (0,5369) XM_854937 SLC6A11 solute carrier family 6 
(neurotransmitter transporter GABA)  
neurotransmitter 
A_11_P0000023510 2,317 (0,5339) TC67847     Myosin Va variant (Fragment) partial 
(18%)  
A_11_P132936 2,283 (0,5572) DR105897     Canine cardiovascular system  
A_11_P089701 2,252 (0,5575) ENSCAFT00000003039 ALDH1L2 aldehyde dehydrogenase 1 family 
member L2 
Probable 10-formyltetrahydrofolate 
dehydrogenase ALDH1L2  
A_11_P0000018162 2,191 (0,5339) DN872189     Dog eye cornea 
A_11_P0000015832 2,15 (0,5339) DN427137     Canis familiaris cDNA clone 
CLN10816113  
A_11_P102006 2,134 (0,5339) ENSCAFT00000008863 PFKP phosphofructokinase platelet glycolysis 
A_11_P159778 2,132 (0,5629) TC53683     Homer homolog 3 (Drosophila) 
partial (30%)  
A_11_P0000029381 2,108 (0,5339) ENSCAFT00000007795 PCDH8 protocadherin 8 Cell adhesion 
A_11_P0000033238 2,03 (0,5339) ENSCAFT00000031460       
A_11_P0000026847 2,029 (0,5572) ENSCAFT00000004939 GGCT gamma-glutamyl cyclotransferase glutation metabolism 
Down regulated genes  
A_11_P0000023399 -2,194 (0,5563) ENSCAFT00000021079 TCEA3 transcription elongation factor A (SII) 
3 
Transcription elongation factor  
A_11_P128391 -3,005 (0,5572) XM_535721 ABI3BP ABI family member 3 (NESH) binding 
protein 
ABI gene family 
A_11_P0000019920 -2,517 (0,5572) NM_001003202 TJP3 tight junction protein 3 (zona 
occludens 3) 
Tight junction 
A_11_P0000021517 -2,516 (0,5339) DN273224     Canis familiaris cDNA clone 
LIB30321_003_B03 mRNA 
sequence  
A_11_P0000016997 -2,246 (0,5572) XM_548082 LOC490959 similar to WNK lysine deficient 
protein kinase 4 
Kinase 
A_11_P103441 -2,242 (0,5572) ENSCAFT00000021079 TCEA3 transcription elongation factor A (SII) 
3 
Transcription elongation factor 
A_11_P0000023757 -2,235 (0,5339) ENSCAFT00000015999 CMBL carboxymethylenebutenolidase 
homolog (Pseudomonas) 
Bioactivating hydrolase 
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Table 3: High significant (p<0.01) at least four fold up or down regulated gene 
expression in only CPV3 affected tissue samples compared to the control. 
Identifier log2 Ratio_CPV3 
(fdr_CPV3) 
PrimaryAccession GeneSymbol GeneName Description 
Up regulated genes      
A_11_P181438 2,772 (0,2961) NM_001097544 PAX6 paired box 6 Transcriptionfactor 
A_11_P0000027732 2,552 (0,3265) NM_001097544 PAX6 paired box 6 Transcriptionfactor 
A_11_P0000015553 2,509 (0,2261) DN409432     Canis familiaris cDNA clone 
CLN9365865  
A_11_P0000022344 2,454 (0,02144) TC69055     Mitochondrial ribosomal protein 
L16  
A_11_P089591 2,367 (0,2043) ENSCAFT00000002672 MCM5 minichromosome maintenance 
complex component 5 
DNA replication licensing factor, 
cell cycle deregulation 
A_11_P085321 2,272 (0,2342) ENSCAFT00000006021 ORC1L origin recognition complex subunit 1-
like  
Replications factor 
A_11_P090876 2,056 (0,2603) ENSCAFT00000001525 KIFC1 kinesin family member C1 cell cycle: chromoseme movement 
A_11_P0000024589 2,027 (0,1961) ENSCAFT00000031608     DNA replication factor Cdt1  
A_11_P0000031692 2,022 (0,2979) ENSCAFT00000037553 LOC488258 similar to Histone H1.2 (H1d) Histone protein 
A_11_P0000016334 2,021 (0,276) CX987798     Canis familiaris testis cDNA Canis 
familiaris cDNA mRNA 
Down regulated 
genes 
     
A_11_P0000020888 -2,019 (0,3283) ENSCAFT00000003739 TECRL trans-2 3-enoyl-CoA reductase-like Steroid 5-alpha-reductase 2-like 2 
protein   
A_11_P114966 -3,375 (0,2261) ENSCAFT00000026677 GDPD2 glycerophosphodiester 
phosphodiesterase domain 
containing 2 
Glycerophosphodiester 
phosphodiesterase 
A_11_P0000025698 -3,178 (0,276) ENSCAFT00000026677 GDPD2 glycerophosphodiester 
phosphodiesterase domain 
containing 2 
Glycerophosphodiester 
phosphodiesterase  
A_11_P146113 -2,768 (0,3358) XM_843618 LOC607732 similar to 60S ribosomal protein L37a Ribosomal protein 
A_11_P0000015771 -2,37 (0,2261) DN425546     Canis familiaris cDNA clone 
CLN10814030  
A_11_P0000020109 -2,172 (0,1835) NM_001005258 CCL21 chemokine (C-C motif) ligand 21 Chemokine ligand 
A_11_P125231 -2,159 (0,1127) XM_848166 LOC474960 similar to CG32333-PA isoform A  
A_11_P091981 -2,151 (0,3283) ENSCAFT00000005805     Popeye domain-containing protein 
3  
A_11_P0000020548 -2,098 (0,2404) ENSCAFT00000003030 NUDT2 nudix (nucleoside diphosphate linked 
moiety X)-type motif 2 
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Table 4: High significant (p<0.01) at least four fold up or down regulated gene 
expression in only CPV5 affected tissue samples compared to the control. 
Identifier log2 Ratio_CPV5 
(fdr_CPV5) 
PrimaryAccession GeneSymbol GeneName Description 
Up regulated genes 
A_11_P0000027041 3,81 (0,2453) ENSCAFT00000010061 TMCC3 transmembrane and coiled-coil 
domain family 3 
transmembran protein 
A_11_P050936 2,821 (0,3334) NM_001114666 ARX aristaless related homeobox mental retardation 
A_11_P0000013614 2,796 (0,2421) CO719715     muscle Canis familiaris cDNA 3'  
A_11_P000006555 2,646 (0,2936) CO585953     brain Canis familiaris cDNA  
A_11_P052151 2,533 (0,3357) ENSCAFT00000035299 LOC610532 similar to Olfactory receptor 7A5  Olfactory receptor  
A_11_P096371 2,505 (0,1946) ENSCAFT00000024923 DAGLB diacylglycerol lipase beta lipase 
A_11_P060766 2,469 (0,3575) ENSCAFT00000035314       
A_11_P000008021 2,42 (0,2729) CO600368     testis Canis familiaris  
A_11_P0000027777 2,374 (0,3071) XM_540616 APLNR apelin receptor apelin receptor on cell surface 
A_11_P000005291 2,355 (0,2453) CF411798      
A_11_P139526 2,311 (0,2438) XM_536395 LOC479252 similar to Vinculin (Metavinculin) adherens junctions 
A_11_P133981 2,292 (0,3606) CX990747     Canis familiaris testis cDNA  
A_11_P000005041 2,27 (0,3396) CF410968      
A_11_P0000031271 2,253 (0,2756) ENSCAFT00000014087 HUNK hormonally up-regulated Neu-
associated kinase 
Serine/threonine-protein kinase 
A_11_P085301 2,252 (0,2421) ENSCAFT00000005958 SHCBP1 SHC SH2-domain binding protein 1  
A_11_P137786 2,245 (0,3357) CF410611      
A_11_P0000025585 2,211 (0,3396) AF082505     Canis familiaris T cell receptor beta  
A_11_P102756 2,2 (0,245) ENSCAFT00000013773     Coiled-coil domain-containing protein  
A_11_P000006860 2,16 (0,245) CO589594     brain Canis familiaris cDNA  
A_11_P0000017582 2,092 (0,3575) DN866257     Dog eye lens 
A_11_P0000013085 2,088 (0,3575) CO709729     muscle Canis familiaris cDNA  
A_11_P0000022158 2,086 (0,3637) ENSCAFT00000023729 LOC476669 similar to Gamma-interferon 
inducible lysosomal thiol reductase 
precursor  
 
A_11_P0000017598 2,079 (0,2198) DN866460     Dog eye lens 
A_11_P054881 2,073 (0,3782) X66173      Na K-ATPase  
A_11_P000003861 2,054 (0,245) BU751593     Canine heart normalized cDNA  
A_11_P121531 2,051 (0,2851) XM_537223 LOC480101 similar to SET and MYND domain 
containing 3 
 
A_11_P0000029906 2,05 (0,2343) ENSCAFT00000039833 STMN4 stathmin-like 4  
A_11_P0000013414 2,007 (0,2453) CO716705     muscle Canis familiaris cDNA 
Down regulated genes 
A_11_P0000015591 -2,002 (0,3396) XM_843905 TMEM52 transmembrane protein 52 transmembrane protein  
A_11_P149068 -3,018 (0,3723) ENSCAFT00000003358 PDK4 pyruvate dehydrogenase kinase 
isozyme 4 
Citric acid cycle 
A_11_P0000040538 -2,797 (0,3491) XM_849378 ASB2 ankyrin repeat and SOCS box-
containing 2 
Cytocrin suppressor 
A_11_P072941 -2,639 (0,3124) ENSCAFT00000038852     PDZ domain-containing protein  
A_11_P214793 -2,633 (0,2453) XM_844878 JPH1 junctophilin 1 junctional complex 
A_11_P180453 -2,541 (0,2219) NM_001003332 PLN phospholamban heart muscle 
A_11_P222388 -2,535 (0,3575) XM_853354 CAP2 CAP adenylate cyclase-associated 
protein 2 (yeast) 
 
A_11_P119121 -2,329 (0,2453) XM_844878 JPH1 junctophilin 1 junctional complex 
A_11_P0000014907 -2,212 (0,3676) DN371046     Canis familiaris cDNA clone  
A_11_P157188 -2,137 (0,2219) TC52285     Alpha/beta hydrolase  
A_11_P0000033661 -2,128 (0,3575) ENSCAFT00000018909 FITM1 fat storage-inducing 
transmembrane protein 1 
Fat storage 
A_11_P0000015569 -2,027 (0,2219) DN411291     Canis familiaris cDNA clone 
CLN10728147  
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Table 5: High significant (p<0.01) at least four fold up or down regulated gene 
expression in two viruses affected tissues compared to the control. (a): Up or down 
regulated genes in CPV1 and CPV3 compared to the control; (b): Up or down 
regulated genes in CPV1 and CPV5 compared to the control; (c): Up or down 
regulated genes in CPV3 and CPV5 compared to the control; (d): Up or down 
regulated genes in all CPV1, CPV3 and CPV5 compared to the control. 
(a) 
 
(b) 
Identifier log2 Ratio_CPV1 
(fdr_CPV1) 
log2 Ratio_CPV5 
(fdr_CPV5) 
PrimaryAccession GeneSymbol GeneName Description 
Up regulated genes 
A_11_P0000023190 3,787 (0,5364) 2,882 (0,391) NM_001145170 CA2 carbonic anhydrase II Metalloenzyme 
 
(c) 
Identifier log2 Ratio_CPV3 
(fdr_CPV3) 
log2 Ratio_CPV5 
(fdr_CPV5) 
PrimaryAccession GeneSymbol GeneName Description 
Up regulated genes 
A_11_P170638 2,063 (0,06834) 2,751 (0,01015) XM_856253 DAGLB diacylglycerol lipase beta Axonal growth 
 
(d) 
 
 
 
Identifier log2 Ratio_CPV1 
(fdr_CPV1) 
log2 Ratio_CPV3 
(fdr_CPV3) 
PrimaryAccession GeneSymbo
l 
GeneName Description 
Up regulated genes       
A_11_P0000040430 2,605 (0,5339) 2,376 (0,2948) TC56305     NHP2 non-histone 
chromosome protein 2-like 1, 
partial (28%)  
Down regulated genes       
A_11_P050111 -2,763 (0,5369) -2,453 (0,3063) NM_001103217 CGN cingulin tight junction 
A_11_P106551 -2,673 (0,5572) -2,326 (0,06731) ENSCAFT00000025298 ALOX12 arachidonate 
12-lipoxygenase 
angiogenese 
A_11_P050151 -2,172 (0,5339) -2,312 (0,2579) NM_001003332 PLN phospholamban calcium pump of cardiac 
sarcoplasmic reticulum 
A_11_P108291 -2,042 (0,5339) -2,069 (0,2243) ENSCAFT00000032309     cytosceleton 
Identifier log2 Ratio_CPV1 
(fdr_CPV1) 
log2 Ratio_CPV3 
(fdr_CPV3) 
log2 Ratio_CPV5 
(fdr_CPV5) 
PrimaryAccession GeneSymbol GeneName Description 
Up regulated genes        
 4.918 (0.5339) 4.865 (0.2644) 4.816 (0.3357) ENSCAFT00000004
630 
KLK8 kallikrein-
related 
peptidase 8 
Kallikrein-9 
Precursor, 
Peptidase 
Down regulated genes        
 -2.385 (0.00746) -2.153 (0.000432) -2.58 (0.003915) CN005540 MT3 metallothion
ein 3 
Brain - Cerebellum 
Library  
 -2.667 (0.002943) -2.349 (0.002191) -2.052 (0.006194) XM_540147 VIT vitrin PREDICTED: Canis 
familiaris similar to 
vitrin transcript  
 -2.903 (0.007522) -2.016 (0.005241) -2.506 (0.003035) ENSCAFT00000010
325 
CCRL1 chemokine 
(C-C motif) 
receptor-like 
1 
C-C chemokine 
receptor type 
 -3.319 (0.007177) -3.985 
(0.0009268) 
-4.972 (0.001332) ENSCAFT00000039
761 
MUSTN1 musculoskel
etal 
embryonic 
nuclear 
protein 1 
Musculoskeletal 
embryonic nuclear 
protein  
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Table 6: Enrichment analysis of differently expressed genes performed by using 
GeneGO. For enriched pathway maps, process networks and GO processes, the 
total number of assigned genes and the percentage of the differently expressed 
genes in the virus infected tissues are listed. The p-value are given in brackets.  
Enrichment by Pathway Maps Total %CPV1 (p-
value) 
%CPV3 (p-
value) 
%CPV5 (p-
value) 
Cell cycle_The metaphase checkpoint 36 5.6 (9.01E-02) 30.6 (2.66E-11) 63.9 (1.96E-15) 
Cell cycle_Role of APC in cell cycle 
regulation 
32 6.3 (7.35E-02) 31.3 (1.72E-10) 62.5 (2.57E-13) 
Cell cycle_Spindle assembly and 
chromosome separation 
33 15.2 (8.59E-05) 36.4 (2.91E-13) 48.5 (1.08E-08) 
Cell cycle_Chromosome condensation in 
prometaphase 
21 4.8 (2.57E-01) 47.6 (1.12E-12) 66.7 (3.07E-10) 
Cell cycle_Sister chromatid cohesion 22 4.5 (2.67E-01) 31.8 (9.21E-08) 59.1 (1.16E-08) 
DNA damage_ATM/ATR regulation of 
G1/S checkpoint 
32 6.3 (7.35E-02) 15.6 (2.83E-04) 43.8 (4.53E-07) 
DNA damage_ATM / ATR regulation of 
G2 / M checkpoint 
26 3.8 (3.07E-01) 11.5 (1.21E-02) 46.2 (1.52E-06) 
DNA damage_Nucleotide excision repair 36 2.8 (3.99E-01) 8.3 (2.89E-02) 38.9 (2.53E-06) 
Cell cycle_Role of SCF complex in cell 
cycle regulation 
29 3.4 (3.36E-01) 13.8 (1.92E-03) 41.4 (6.21E-06) 
     
Enrichment by Process Networks     
Cell cycle_Core 115 4.3 (1.24E-01) 20.9 (2.97E-14) 53.0 (1.39E-19) 
Cell cycle_S phase 149 3.4 (2.57E-01) 20.8 (4.16E-18) 47.7 (3.74E-19) 
Cell cycle_Mitosis 179 4.5 (5.34E-02) 15.1 (2.66E-12) 39.1 (2.01E-13) 
Cytoskeleton_Spindle microtubules 109 6.4 (1.24E-02) 19.3 (6.82E-12) 40.4 (2.01E-09) 
Cell cycle_G2-M 206 4.4 (4.72E-02) 12.6 (4.14E-10) 33.5 (1.10E-09) 
DNA damage_Checkpoint 124 4.0 (1.56E-01) 11.3 (2.00E-05) 37.9 (6.52E-09) 
Cell cycle_G1-S 163 5.5 (1.25E-02) 12.3 (7.94E-08) 33.1 (1.11E-07) 
DNA damage_DBS repair 116 4.3 (1.28E-01) 4.3 (2.74E-01) 33.6 (4.32E-06) 
DNA damage_BER-NER repair 110 4.5 (1.08E-01) 12.7 (4.92E-06) 33.6 (7.49E-06) 
Proteolysis_Ubiquitin-proteasomal 
proteolysis 
166 4.2 (8.70E-02) 6.0 (2.86E-02) 30.1 (7.56E-06) 
     
Enrichment by GO Processes     
mitotic cell cycle 771 3.6 (2.45E-03) 9.9 (3.87E-30) 35.8 (1.58E-44) 
interphase of mitotic cell cycle 452 4.0 (5.62E-03) 8.6 (6.94E-14) 34.1 (1.21E-22) 
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Table7: Relative expression (qRT-PCR) of the cellular transcripts of KLK8, MCM5, 
ORC1 and PAX compared to the GAPDH expression in CPV1, CPV3 and CPV5 
affected tissue samples and their statistical significance (p value). 
 KLK8 MCM5 ORC1 PAX 
virus increased p < increased p < increased p < increased p < 
CPV1 25,5 ± 25,6  0,02 1,8 ± 0,8 0,51 1,7 ± 1,1 0,66 1,9 ± 2,4 0,88 
CPV3 23,0 ± 13,3 0,01 7,1 ±0,9 0,05 6,8 ±1,6 0,01 34,4 ± 26,1 0,01 
CPV5 23,3 ± 7,9 0,01 2,9 ± 1,6 0,32 3,2 ± 1,1 0,01 3,4 ± 3,1 0,07 
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